Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | MLYCD | O95822 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94716 | 0.83 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL94715 | 0.83 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3944170 | 0.83 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3946941 | 0.83 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL12567219 | 0.82 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL23340686 | 0.81 | ELANE (0.34) | CYP2D6ELANE | |
| SCHEMBL19750508 | 0.81 | CYP2D6 (0.40) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL1239583 | 0.81 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL12861679 | 0.81 | CYP2D6 (0.49) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7324935 | 0.81 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119212978-A | Oxoindolinyl amide derivatives for inhibiting NLRP3 and use thereof | 万特斯治疗美国公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-9434747-B2 | Methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433626-B2 | Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9271971-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9211287-B2 | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9199996-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150258075-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130217675-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-22 | — | — | US | disclosed |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130172320-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120161296-A1 | MULTIPLE PATTERNING USING IMPROVED PATTERNABLE LOW-k DIELECTRIC MATERIALS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011103433-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011038163-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258075-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | HTR1B, HTR2B, HTR2A | CYP2D6 952/4885HDAC3 3971/4885HDAC1 4370/4885 |
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2D6 428/4885HDAC3 4112/4885HDAC1 4372/4885 |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2D6 428/4885HDAC3 4112/4885HDAC1 4372/4885 |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | CYP2D6 3380/4885HDAC3 3448/4885HDAC1 3087/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP2D6 316/4885HDAC3 1557/4885HDAC1 764/4885 |
| US-20130172320-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2D6 230/4885HDAC3 3476/4885HDAC1 4363/4885 |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | CYP2D6 4412/4885HDAC3 1926/4885HDAC1 2427/4885 |
| US-20130217675-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2D6 230/4885HDAC3 3476/4885HDAC1 4363/4885 |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2D6 420/4885HDAC3 4157/4885HDAC1 4373/4885 |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2D6 230/4885HDAC3 3476/4885HDAC1 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.